Randomized trial · people
Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a direct head-to-head trial, tirzepatide led to more weight and waist loss than semaglutide over 72 weeks, and gut-related side effects were the most common in both groups.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 751
- Published
- 2025
- Journal
- N Engl J Med
What they tested
The team tested whether tirzepatide or semaglutide led to more weight loss in adults with obesity who did not have type 2 diabetes.
How the study was done
A phase 3b, randomized, open-label trial in 751 adults with obesity but without type 2 diabetes. Each person was assigned to the highest dose they could tolerate of either tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg), injected under the skin once a week for 72 weeks.

Model. Individual results vary.
What they found
At week 72, body weight changed by an average of -20.2% on tirzepatide and -13.7% on semaglutide (P<0.001). Waist size shrank by 18.4 cm on tirzepatide and 13.0 cm on semaglutide (P<0.001). People on tirzepatide were more likely to lose at least 10%, 15%, 20% and 25% of their weight. In both groups the most common side effects were gut-related, mostly mild to moderate, and they came mainly while doses were being raised.
What it doesn’t show
It was an open-label trial rather than a blinded one, and it was funded by Eli Lilly. It included only adults without type 2 diabetes, so it does not show how the two drugs compare in people with diabetes.
The paper
Aronne et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025.
The compounds
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: up to 17.5% weight loss at 52 weeks in SURMOUNT-CNRandomized trial · people · 2024
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.